Dossier - 31/03/2014 Peptides – diverse molecules of life Peptides exist in all organisms, wherever there are cells. The range of their physiological functions is huge. Biologically active peptides can act as hormones, neurotransmitters, growth factors as well as toxins and antibiotics. This is what makes them highly interesting drug leads. They are used for the treatment of autoimmune diseases, cancer and other diseases. Despite some drawbacks, peptides are gaining in importance as candidates for drugs…https://www.gesundheitsindustrie-bw.de/en/article/dossier/peptides-diverse-molecules-of-life
Article - 24/03/2014 Vaccine against papillomaviruses protects from skin cancer Papillomaviruses are thought to cause non-melanoma skin cancer in people exposed to UV radiation, especially those who have suppressed immune systems. Researchers from the German Cancer Research Center (DKFZ) and the Charité University Hospital in Berlin have developed a vaccine that protects mice against such skin tumours. The vaccine is even effective in mice that have previously been infected with papillomaviruses and that have suppressed…https://www.gesundheitsindustrie-bw.de/en/article/news/vaccine-against-papillomaviruses-protects-from-skin-cancer
Press release - 11/03/2014 CureVac Wins Two Million EUR from Inaugural European Commission Vaccine Prize 10 March 2014 CureVac a German clinical stage biopharmaceutical company today announced that it has won the inaugural European Commission Vaccine Prize. The EU has dedicated the prize of two million Euros in an effort to stimulate innovative solutions for vaccine transportation and storage where cold chain cannot be guaranteed. CureVacs RNActive vaccine technology based on messenger RNA mRNA convinced the panel of judges of its potential as a…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-wins-two-million-eur-from-inaugural-european-commission-vaccine-prize
Article - 27/01/2014 immatics biotechnologies GmbH: active against cancer immatics biotechnologies GmbH is a biopharmaceutical company wholly concerned with the development of advanced immunotherapies that are active against different types of cancer, including renal cell, colorectal, brain and gastric cancer. The company currently has a workforce of 80 at its headquarters in Tübingen and subsidiary in Munich. It capitalises on the know-how in the analysis of tumour cells and vaccine development gained through its…https://www.gesundheitsindustrie-bw.de/en/article/news/immatics-biotechnologies-gmbh-active-against-cancer
Article - 20/01/2014 Microarray copier – for copying DNA, RNA and protein arrays Dr. Günter Roth from the Centre for Biological Systems Analysis at the University of Freiburg is working on the development of a microarray copier that can almost at the push of a button copy arrays of any type of molecule DNA RNA and proteins from next-generation sequencing chips onto standard slides thereby combining the world of microarrays with the sequencing world. The approach has a huge application potential for the production of…https://www.gesundheitsindustrie-bw.de/en/article/news/microarray-copier-for-copying-dna-rna-and-protein-arrays
Press release - 15/10/2013 Biotech financing in Baden-Württemberg: immatics raises 34 million Euros The immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer, today announced that it has closed a 34 million Euros Series D financing round. The funding round was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, MIG-advised funds and AT Impf GmbH. Under the terms of the fundraising, immatics will receive…https://www.gesundheitsindustrie-bw.de/en/article/press-release/biotech-financing-in-baden-wuerttemberg-immatics-raises-34-million-euros
Article - 30/09/2013 CureVac GmbH: RNA-based vaccines and immunotherapies CureVac GmbH, a biopharmaceutical company based in Tübingen, develops immunotherapies for cancer along with prophylactic vaccines based on its proprietary messenger RNA (mRNA) technology platform. CureVac also uses RNA for developing adjuvants. Two clinical trials, a Phase I trial in non-small cell lung cancer (NSCLC) and a Phase IIb trial in prostate cancer, are currently underway to test the efficiency of mRNA-based drugs in treating cancer and…https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-gmbh-rna-based-vaccines-and-immunotherapies
Article - 08/07/2013 Christine Goffinet: independent and successful AIDS researchers Christine Goffinet, 36, from the Institute of Molecular Virology at the University of Ulm has already received numerous awards for her research on AIDS. She was recently awarded a scholarship for postdoctoral lecture qualification under the Margarete von Wrangell Habilitation Programme. However, before she became a virologist, Goffinet chose a career path that was quite different from the standard career path seen on many scientific CVs.https://www.gesundheitsindustrie-bw.de/en/article/news/christine-goffinet-independent-and-successful-aids-researchers
Article - 17/05/2013 Dengue fever, the neglected infectious disease Dengue fever is the most common infectious disease transmitted by mosquitoes. The disease is spreading in Europe and Germany, an upward trend that is due to increased long-distance travel. There are no specific drugs or vaccine for dengue, which is why an international research network has been established to improve the management of the disease. The consortium is coordinated by the Department of Tropical Medicine at Heidelberg University.https://www.gesundheitsindustrie-bw.de/en/article/news/dengue-fever-the-neglected-infectious-disease
Press release - 30/04/2013 Impressions from the 2013 BIO International Convention in Chicago A trade fair turns 20 and an industrial sector is coming of age. Where does BIO stand today? The number of exhibitors has slightly decreased the conference is characterised by general themes and trends and partnering has become the most important and indispensable part of the global event for biotechnology. What was once a gold rush atmosphere has given way to an experienced self-confidence about the economic importance of biotechnology. https://www.gesundheitsindustrie-bw.de/en/article/press-release/impressions-from-the-2013-bio-international-convention-in-chicago
Dossier - 01/04/2013 Retroviruses: from infectious agent to therapeutic assistant Viruses are infectious particles that use the machinery and metabolism of a host cell to replicate. Despite some similarities with accepted forms of life viruses are not considered as such. The family of retroviruses is particularly known for its most notorious representative i. e. the human immunodeficiency virus HIV which leads to AIDS and for which no cure or effective vaccine is currently available. However retroviruses are not only of…https://www.gesundheitsindustrie-bw.de/en/article/dossier/retroviruses-from-infectious-agent-to-therapeutic-assistant
Article - 04/02/2013 G protein-coupled receptors and their importance for research and development Brian Kobilka and Robert Lefkowitz were awarded the 2012 Nobel Prize in Chemistry for their groundbreaking discoveries of the inner workings of G protein-coupled receptors (GPCRs). These transmembrane receptors play a key role in the processing of odours and the recognition of hormones. The work of the two American scientists has had an impact on many researchers around the world. In the following interview, Professor Dr. Daniel Legler, head of…https://www.gesundheitsindustrie-bw.de/en/article/news/g-protein-coupled-receptors-and-their-importance-for-research-and-development
Press release - 13/11/2012 immatics’ renal cancer vaccine IMA901 completes phase 3 patient recruitment immatics biotechnologies GmbH announced that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma RCC. The first interim overall survival results are expected during the first half of 2014.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-renal-cancer-vaccine-ima901-completes-phase-3-patient-recruitment
Press release - 12/11/2012 immatics appoints Peter Chambré as Chairman immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced the appointment of Peter Chambré as Chairman of the Board with immediate effect. Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He will replace Thomas Widmann, who has…https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-peter-chambr-as-chairman
Press release - 30/10/2012 DKFZ and Genetic Immunity Sign Collaboration Agreement to Develop HPV Therapeutic Vaccine Genetic Immunity, Budapest, a leader in immunotherapy technology product development, and DKFZ (German Cancer Research Center, Heidelberg, Germany) signed a collaborative agreement to develop a DNA-based vaccine for the treatment of Human Papilloma Virus (HPV) infection that causes cervical cancer and other cancers of the anus, penis, vulva, vagina, and oropharynx. Present HPV vaccines (Cervarix, Gardasil) have no therapeutic effect on…https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-and-genetic-immunity-sign-collaboration-agreement-to-develop-hpv-therapeutic-vaccine
Article - 15/10/2012 gerbion®: hunting down pathogens Detecting viruses, bacteria or parasites in human, animal, food and environmental samples is routine for the staff of gerbion GmbH & Co. KG. The company has been using virological, microbiological and serological methods for many years, but is now also using cutting-edge molecular biology methods for detecting pathogens. The founders of the Kornwestheim-based diagnostics company have concentrated on own research work and the development of…https://www.gesundheitsindustrie-bw.de/en/article/news/gerbion-hunting-down-pathogens
Press release - 18/09/2012 CureVac Secures €80 Million in Series D Financing CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, announced on september 18 the completion of an €80 million financing round with its main investor, dievini Hopp BioTech Holding. In the next years, CureVac will use the proceeds mainly to advance the development of its two lead RNActive® cancer vaccines against prostate cancer and non-small cell lung cancer (NSCLC),…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-secures-80-million-in-series-d-financing
Article - 03/09/2012 Systems biology and hepatitis C research The international research project SysPatho aims to advance the understanding of HCV (hepatitis C virus) infections using systems biology approaches. The goal of the project coordinated by Universität Heidelberg is to develop new mathematical and computational methods to reconstruct HCV-infected hepatocytes, which can be used to identify new drug targets and help treat this dangerous disease.https://www.gesundheitsindustrie-bw.de/en/article/news/systems-biology-and-hepatitis-c-research
Press release - 07/08/2012 immatics announces publication of IMA901 cancer vaccine data in Nature Medicine immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine. The paper highlights that renal cell carcinoma patients experience longer survival times when their immune system produces an immune response to…https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-publication-of-ima901-cancer-vaccine-data-in-nature-medicine
Article - 16/07/2012 Laupheim to become an international forum for biomanufacturing The 2nd Laupheimer Zelltage conference organized by Rentschler Biotechnologie GmbH in Laupheim on 11th and 12th June 2012 focused on “Bioprocess light”. Twelve experts from applied research institutions and biotech companies from Germany and abroad provided the 200 or so guests with information on how modern bioproduction methods can be made simpler, more robust, cheaper, more reliable and hence more competitive.https://www.gesundheitsindustrie-bw.de/en/article/news/laupheim-to-become-an-international-forum-for-biomanufacturing
Press release - 01/06/2012 immatics wins 2012 TiE50 Award Immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that it has been named a 2012 TiE50 winner. These prestigious awards recognize entrepreneurship, innovation and management excellence within the life sciences, software, internet, mobile and energy sectors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-wins-2012-tie50-award
Dossier - 30/04/2012 Human infectious diseases: new threats The serious EHEC outbreak in Germany in 2011, the 2009 swine flu pandemic, the bird flu pandemic in 2005 and 2006 and the SARS outbreak in China in 2003, all of which have fuelled the fear of devastating epidemics for many people in Germany, have fortunately all been contained – at least up until now. However, experts warn of new dangerous pathogens that are spreading as a result of globalization and global climate warming. This is leading to new…https://www.gesundheitsindustrie-bw.de/en/article/dossier/human-infectious-diseases-new-threats
Press release - 18/04/2012 immatics appoints Dr. Rainer Kramer as Chief Business Officer immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing therapeutic vaccines that are active against cancer, today announced the appointment of Dr. Rainer Kramer as Chief Business Officer (CBO) with immediate effect. In this newly created role, Dr. Kramer will lead immatics’ Business Development Unit in order to create optimal value from the Company’s pipeline of therapeutic cancer vaccines.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-dr-rainer-kramer-as-chief-business-officer
Article - 20/02/2012 Microporation: an innovative laser replaces jabs People who are afraid of needles now have something to celebrate: hypodermic needles, which have long been the key instrument for administering drugs used to treat allergies and diseases as well as for vaccinations, now have a serious competitor. The minimally invasive P.L.E.A.S.E. ® platform developed by Pantec Biosolutions AG combines a laser device and stick-on patches to deliver drugs transdermally and painlessly into the bloodstream. The…https://www.gesundheitsindustrie-bw.de/en/article/news/microporation-an-innovative-laser-replaces-jabs
Press release - 02/02/2012 Colorectal cancer: Phase II results with cancer vaccine IMA910 are positive immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced positive results from its Phase II clinical trial with IMA910 in patients with advanced colorectal cell carcinoma (CRC) which were presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco. IMA910 comprises 13 tumor-associated…https://www.gesundheitsindustrie-bw.de/en/article/press-release/colorectal-cancer-phase-ii-results-with-cancer-vaccine-ima910-are-positive